MPO and glycogen storage disease VI: Thereis now strong evidence that HDL is a selective in vivo target for MPO-catalyzedoxidation, that may represent a specific molecular mechanism for converting thecardioprotective lipoprotein into a dysfunctional form, raising the possibilitythat the enzyme represents a potential therapeutic target for preventingvascular disease in humans [5].Zhou et al. [6] showed that atorvastatinreduced serum MPO and CRP concentrations in patients with ACS.